Aurobindo Pharma Ltd
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
618 / 1328
Position in country
2090 / 4091
Net income margin, %
12.7
2.8
EBITDA margin, %
21.7
10.8
Revenue CAGR 3Y, %
2.4
8.5
Revenue Y, % chg
11.2
0.5
P/E
23
22.7
P/BV
2.2
1.5
P/S
2.2
2.3
EV/S
2.2
2.4
EV/EBITDA
12.3
7.4
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
5.6
51.3
Forward P/E
17
15.6
Dividend Yield, %
0.4
1.7
Forward Dividend Yield, %
0
0.2
Expected dividend per share
0
0
Dividend Ex Date
2024-02-20
Competitors
Ranks
-
Sun Pharmaceutical Industries Ltd
00%
-
Cipla Ltd
00%
-
Torrent Pharmaceuticals Ltd
00%
-
Zydus Lifesciences Ltd
00%
-
Dr Reddy's Laboratories Ltd
00%
-
Alkem Laboratories Ltd
00%
-
Aurobindo Pharma Ltd
00%
-
IPCA Laboratories Ltd
00%
-
Lupin Ltd
00%
-
Mankind Pharma Ltd
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
India
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
7654
Ticker
ARBN.NS
ISIN
INE406A01037
IPO date
1995-01-19
Availability on Russian exchanges
No
Reporting for
2024-02-10
Date fact. publication of reports
2023-12-31
Company Description
Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: